Payment overview · 2025
General Payments
$225.37
13 reported records · 4 companies
Healthcare provider profile · identity verified
Christopher Glenn Koman, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PITTSBURGH, PA · NPI 1437149002
Verified facts
What the public records show
CMS Open Payments records show Christopher Glenn Koman, M.D. received $225.37 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 63.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $143.53 | 63.7% | 8 | 2025 |
| MEDICOMP INC | Unresolved — no canonical attribution shown | $35.05 | 15.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.47 | 13.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.32 | 7.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $225.37 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $61.45 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.32 | 5 | 2025 |
Source payment records
|
|||||
| TELEPATCH CARDIAC MONITOR Normalized: telepatch cardiac monitor |
Device | MEDICOMP INC | $35.05 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $8.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 595 | 154 |
| Levothyroxine Sodium | Levothyroxine Sodium | 460 | 113 |
| Lisinopril | Lisinopril | 360 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 319 | 82 |
| Sertraline Hcl | Sertraline Hcl | 284 | 49 |
| Furosemide | Furosemide | 262 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 255 | 72 |
| Metoprolol Tartrate | Metoprolol Tartrate | 233 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 193 | 57 |
| Losartan Potassium | Losartan Potassium | 190 | 56 |
| Gabapentin | Gabapentin | 180 | 41 |
| Eliquis | Apixaban | 169 | 53 |
| Trazodone Hcl | Trazodone Hcl | 168 | 53 |
| Potassium Chloride | Potassium Chloride | 167 | 39 |
| Omeprazole | Omeprazole | 157 | 43 |
| Carvedilol | Carvedilol | 156 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 145 | 42 |
| Simvastatin | Simvastatin | 139 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 38 |
| Famotidine | Famotidine | 121 | 29 |
| Metformin Hcl | Metformin Hcl | 121 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 30 |
| Mirtazapine | Mirtazapine | 117 | 23 |
| Tramadol Hcl | Tramadol Hcl | 110 | 32 |
| Meloxicam | Meloxicam | 106 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 96 | 23 |
| Xarelto | Rivaroxaban | 94 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 91 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 16 |
| Atenolol | Atenolol | 85 | 20 |
| Lorazepam | Lorazepam | 83 | 16 |
| Finasteride | Finasteride | 77 | 20 |
| Donepezil Hcl | Donepezil Hcl | 76 | 14 |
| Ozempic | Semaglutide | 76 | 11 |
| Alendronate Sodium | Alendronate Sodium | 73 | suppressed |
| Allopurinol | Allopurinol | 71 | 22 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 67 | 67 |
| Prednisone | Prednisone | 66 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | suppressed |
| Bumetanide | Bumetanide | 61 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 60 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 13 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 58 | 58 |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 23 |
| Synthroid | Levothyroxine Sodium | 53 | 17 |
| Buspirone Hcl | Buspirone Hcl | 52 | 15 |
| Cholestyramine | Cholestyramine (With Sugar) | 52 | 14 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 51 | 11 |
| Midodrine Hcl | Midodrine Hcl | 50 | suppressed |
| Trulicity | Dulaglutide | 49 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 48 | 48 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Alprazolam | Alprazolam | 47 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 46 | 32 |
| Spironolactone | Spironolactone | 46 | 15 |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Jardiance | Empagliflozin | 39 | suppressed |
| Olanzapine | Olanzapine | 39 | suppressed |
| Ezetimibe | Ezetimibe | 38 | 11 |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 30 | 12 |
| Latanoprost | Latanoprost | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Valsartan | Valsartan | 28 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 15 |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 22 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Jantoven | Warfarin Sodium | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Nystatin | Nystatin | 22 | 13 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 21 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Cholestyramine Light | Cholestyramine | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Nystop | Nystatin | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Hydroxyurea | Hydroxyurea | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Cartia Xt | Diltiazem Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Lumigan | Bimatoprost | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Selegiline Hcl | Selegiline Hcl | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Azithromycin | Azithromycin | 12 | 11 |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $225.37 · 13 records | Novo Nordisk Inc | CAPVAXIVE, Cologuard Collection Kit, ENFLONSIA, GARDASIL 9, Ozempic, Rybelsus, TELEPATCH CARDIAC MONITOR, The Cologuard Plus Collection Kit, Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error